PMID- 25496560
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20181202
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 14
DP  - 2014 Dec 13
TI  - The effects of Cordyceps sinensis phytoestrogen on estrogen deficiency-induced 
      osteoporosis in ovariectomized rats.
PG  - 484
LID - 10.1186/1472-6882-14-484 [doi]
LID - 484
AB  - BACKGROUND: Isoflavones are naturally occurring plant chemicals belonging to the 
      "phytoestrogen" class. The aim of the present study was to examine the effects of 
      isoflavones obtained from Cordyceps sinensis (CSIF) on development of estrogen 
      deficiency-induced osteoporosis in ovariectomized rats. METHODS: After the rats 
      were treated orally with CSIF, serum alkaline phosphatase (ALP), tartarate 
      resistant acid phosphatase (TRAP), serum osteocalcin (OC), homocysteine (HCY), 
      C-terminal crosslinked telopeptides of collagen type I (CTX), estradiol and 
      interferongamma (IFN-gamma) level were examined. At the same time, the urine calcium, 
      plasma calcium, plasma phosphorus and the mass of uterus, thymus and body were 
      also examined. RESULTS: The beneficial effects of CSIF on improvement of 
      osteoporosis in rats were attributable mainly to decrease ALP activity, TRAP 
      activity, CTX level and IFN-gamma level. At the same time, CSIF also increase the OC 
      and estradiol level in ovariectomized osteopenic rats. The histological 
      examination clearly showed that dietary CSIF can prevent bone loss caused by 
      estrogen deficiency. CONCLUSION: The significant estrogenic activity of CSIF 
      demonstrated that CSIF has significant estrogenic effects in OVX rats.
FAU - Zhang, Da-wei
AU  - Zhang DW
FAU - Wang, Zhen-lin
AU  - Wang ZL
FAU - Qi, Wei
AU  - Qi W
FAU - Zhao, Guang-yue
AU  - Zhao GY
AD  - Department of Orthopedics, Xi Jing Hospital, the Fourth Military Medical 
      University, Xi'an 710032, People's Republic of China. GuangyueZfmmu@yeah.net.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141213
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Biological Products)
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Collagen Type I)
RN  - 0 (Estrogens)
RN  - 0 (Isoflavones)
RN  - 0 (Phytoestrogens)
RN  - 104982-03-8 (Osteocalcin)
RN  - 27YLU75U4W (Phosphorus)
RN  - 4TI98Z838E (Estradiol)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - EC 3.1.3.2 (Acid Phosphatase)
SB  - IM
MH  - Acid Phosphatase/blood
MH  - Alkaline Phosphatase/blood
MH  - Animals
MH  - Biological Products/pharmacology/*therapeutic use
MH  - Bone Density Conservation Agents/pharmacology/*therapeutic use
MH  - Bone Diseases, Metabolic/blood/drug therapy
MH  - Collagen Type I/metabolism
MH  - Cordyceps/*chemistry
MH  - Estradiol/blood
MH  - Estrogens/deficiency
MH  - Female
MH  - Humans
MH  - Interferon-gamma/blood
MH  - Isoflavones/pharmacology/*therapeutic use
MH  - Osteocalcin/blood
MH  - Osteoporosis/blood/*drug therapy/etiology/pathology
MH  - Ovariectomy
MH  - Phosphorus/blood
MH  - Phytoestrogens/pharmacology/*therapeutic use
MH  - *Phytotherapy
MH  - Rats
MH  - Rats, Wistar
MH  - Uterus/drug effects
PMC - PMC4302055
EDAT- 2014/12/17 06:00
MHDA- 2015/09/04 06:00
PMCR- 2014/12/13
CRDT- 2014/12/16 06:00
PHST- 2014/02/19 00:00 [received]
PHST- 2014/12/10 00:00 [accepted]
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
PHST- 2014/12/13 00:00 [pmc-release]
AID - 1472-6882-14-484 [pii]
AID - 2049 [pii]
AID - 10.1186/1472-6882-14-484 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2014 Dec 13;14:484. doi: 10.1186/1472-6882-14-484.